The Omnipod 5 automated insulin delivery (AID) system has now been made fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes.
Acton, Massachusetts-based Insulet received FDA clearance for Omnipod 5, the latest iteration of its wearable insulin pump, in January. The company designed its Omnipod 5 as a tubeless pod with SmartAdjust technology, the Dexcom G6 CGM and the Omnipod 5 mobile app with an integrated SmartBolus calculator.
Users can download the app onto a compatible smartphone or use the Omnipod 5 controller, provided free with the first prescription. The device provides a Dexcom CGM value and trend to the SmartAdjust technology every 5 minutes. It then predicts where glucose will be 60 minutes into the future before increasing, decreasing or pausing insulin delivery, using the wearer’s desired and customized glucose target to protect against highs and lows.
Insulet said in a news release that Omnipod 5 represents the first tubeless AID system that integrates with Dexcom’s G6 and the only one that offers the option of using the compatible smartphone or Omnipod 5 controller. The company added that it is working to expand its list of compatible smartphones to reach a wider population.
Get the full story at our sister site, Drug Delivery Business News.